SCHEMBL548550

SCHEMBL548550

Cc1cc(C23CC4CC(CC(C4)C2)C3)cc(C23CC4CC(CC(C4)C2)C3)c1O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.46
POLB P06746 1/20 0.46
GAA P10253 1/20 0.46
GFER P55789 1/20 0.46
KMT2A Q03164 1/20 0.46
CNR2 P34972 7/20 0.41
CNR1 P21554 2/20 0.38
LMNA P02545 2/20 0.38
ALDH1A1 P00352 1/20 0.38
NPC1 O15118 1/20 0.37
ACHE P22303 1/20 0.37
RARB P10826 3/20 0.37
RARA P10276 2/20 0.37
RARG P13631 2/20 0.37
EPHX2 P34913 1/20 0.36
MAPT P10636 1/20 0.36
HDAC3 O15379 1/20 0.34
HDAC4 P56524 1/20 0.34
HDAC7 Q8WUI4 1/20 0.34
HDAC2 Q92769 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27451016 0.89 MEN1 (0.52) MEN1POLBGAAGFERKMT2A
SCHEMBL549877 0.87 MEN1 (0.53) MEN1POLBGAAGFERKMT2A
SCHEMBL27199185 0.84 MEN1 (0.56) MEN1POLBGAAGFERKMT2A
SCHEMBL549830 0.82 MEN1 (0.58) MEN1POLBGAAGFERKMT2A
SCHEMBL549486 0.80 MEN1 (0.44) MEN1POLBGAAGFERKMT2A
SCHEMBL548526 0.79 MEN1 (0.54) MEN1POLBGAAGFERKMT2A
SCHEMBL31261477 0.79 MEN1 (0.46) MEN1POLBGAAGFERKMT2A
SCHEMBL31261475 0.79 MEN1 (0.46) MEN1POLBGAAGFERKMT2A
SCHEMBL31261476 0.79 MEN1 (0.46) MEN1POLBGAAGFERKMT2A
SCHEMBL31261474 0.79 MEN1 (0.46) MEN1POLBGAAGFERKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8110614-B2 Adamantane derivative, method for producing the same, and resin composition containing adamantane derivative IDEMITSU KOSAN CO., LTD. (JP) 2012-02-07 US disclosed
US-20100056663-A1 ADAMANTANE DERIVATIVE, METHOD FOR PRODUCING THE SAME, AND RESIN COMPOSITION CONTAINING ADAMANTANE DERIVATIVE IDEMITSU KOSAN CO., LTD. (JP) 2010-03-04 US disclosed
EP-2090563-A1 ADAMANTANE DERIVATIVE, METHOD FOR PRODUCING THE SAME, AND RESIN COMPOSITION CONTAINING ADAMANTANE DERIVATIVE IDEMITSU KOSAN COMPANY LIMITED (JP) 2009-08-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100056663-A1 ADAMANTANE DERIVATIVE, METHOD FOR PRODUCING THE SAME, AND RESIN COMPOSITION CONTAINING ADAMANTANE DERIVATIVE ARCN1, RTN3, CHRNA3 MEN1 3412/4885POLB 3648/4885GAA 2496/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.